Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8384858687888990919293...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma (Pubmed Central) -  May 15, 2021   
    The use of both the combination of nivolumab + ipilimumab and cabozantinib is restricted to intermediate and high-risk patients...Temsirolimus is only approved for high-risk patients.Sunitinib and pazopanib can also be applied as second-line options - for pazopanib the use is restricted to the event of cytokine failure...Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second-line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
  • ||||||||||  lenvatinib / Generic mfg., ibrutinib / Generic mfg.
    Journal:  Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors. (Pubmed Central) -  May 13, 2021   
    The former has the structural role of acting as a scaffold and the functional role of participating in aromatic ring-originated non-bonded interactions with multiple hydrophobic regions in the ATP binding pocket of kinases. The latter ensure water solubility and form hydrogen bonds with the hinge region and other hydrophilic residues of the ATP binding pocket.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) -  May 13, 2021   
    P1b/2,  N=357, Active, not recruiting, 
    The latter ensure water solubility and form hydrogen bonds with the hinge region and other hydrophilic residues of the ATP binding pocket. Trial completion date: Apr 2020 --> Sep 2023 | Trial primary completion date: Apr 2020 --> Aug 2020
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? (Pubmed Central) -  May 13, 2021   
    In IPW-adjusted Cox hazard multivariate analysis, significant prognostic factors for OS after PD were mALBI 2b/3 at PD (HR 1.983, p = 0.021), decline of Eastern Cooperative Oncology Group performance status (ECOG PS) from baseline at PD (HR 3.180, p < 0.001), elevated alpha-fetoprotein (≥100 ng/mL) at introducing LEN (HR 2.511, p = 0.004), appearance of new extrahepatic metastasis (HR 2.396, p = 0.006), positive for hand-foot skin reaction (HFSR) before PD (any grade) (HR 0.292, p < 0.001), and continuing LEN beyond PD (HR 0.297, p < 0.001). When ECOG PS and hepatic reserve function permit, continuing LEN treatment beyond PD, especially in u-HCC patients showed HFSR during LEN treatment, might be a good therapeutic option, at least until a more effective drug as a postprogression treatment after LEN failure is developed.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    [VIRTUAL] Cancer therapy related dysphonia: Analysis of real-world FAERS data. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4922;    
    It is worth noting that some of the suspect medications identified in this study do not have dysphonia listed as known adverse effect on accompanying package insert . Further studies need to be conducted to confirm if causal relationship exists between use of these drugs and development of dysphonia .
  • ||||||||||  [VIRTUAL] Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4664;    
    There was no significant difference in the mOS between pts with R/M ACC who were treated with chemo, EGFRi or TKIs and in those who received ICIs compared to those who did not in our limited patient population . This highlights the need for predictive biomarkers for better patient selection with the goal of personalizing treatment strategies for this disease.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    [VIRTUAL] Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4467;    
    P=N/A
    In this mRCC population receiving routine care in the US, cabozantinib was used more frequently than other TKIs after CPI treatment . Cabozantinib was an effective and well tolerated option post-CPI, with a high response rate in the real-world setting.abozantinib was associated with a significantly higher response rate and a lower discontinuation rate due to AEs; TTD was double that of other TKIs.
  • ||||||||||  Q-Force (quercetin) / Quercegen, Temple University, Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Novel systemic therapies in the treatment of fibrolamellar carcinoma. () -  Apr 29, 2021 - Abstract #ASCO2021ASCO_4318;    
    There is a strong need for effective and tolerable systemic therapies for those with unresectable, relapsed, progressive, or metastatic disease . We have had promising results in treating FLC and prolonging survival with minimal toxicities using novel multi-agent regimens.